Silver Book Fact

A study of a number of osteoporosis treatments found cost-effectiveness ratios as low as $55,000 per QALY.

Mobley, Lee R., Thomas J. Hoerger, John S. Wittenborn, Debroah A. Galuska, and Jaya K. Rao. Cost-Effectiveness of Osteoporosis Screening and Treatment with Hormone Replacement Therapy, Raloxifene, or Alendronate. Medical Decision Making. 2006; 26(2): 194-206. http://mdm.sagepub.com/cgi/content/abstract/26/2/194

Reference

Title
Cost-Effectiveness of Osteoporosis Screening and Treatment with Hormone Replacement Therapy, Raloxifene, or Alendronate
Publication
Medical Decision Making
Publication Date
2006
Authors
Mobley, Lee R., Thomas J. Hoerger, John S. Wittenborn, Debroah A. Galuska, and Jaya K. Rao
Volume & Issue
Volume 26, Issue 2
Pages
194-206
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.  
  • 50% of Repeat Osteoporotic Fractures Could be Avoided
     
  • Raloxifene, a selective estrogen receptor modulator (SERM) has been shown to increase vertebral bone mineral density (BMD) by 2% to 3% after 3 years.  
  • Researchers are looking at the use of micro-computed tomography and magnetic resonance imaging to better understand the relationship between bone structure and fracture risk. Other tools are being evaluated for…  
  • Clinical studies in nutrition and physical activity interventions have proven that fractures can be prevented, even in older individuals, and that they do not need to be a natural consequence…